Biomarker and Prognostic Value of Super-ARMS Detection for EGFR Mutation in Advanced NSCLC
Patients exhibiting metastasis, elevated levels of tumor markers and SUV<sub>max</sub> are more suitable for plasma EGFR mutation testing in clinical NSCLC management. Moreover, a positive plasma ctDNA test not only guides targeted therapy but also predicts a worse prognosis.
Authors
- Lisha Xiao
- Yubiao Guo (ORCID: https://orcid.org/0000-0003-3153-8121)
- Hui Li (ORCID: https://orcid.org/0000-0001-5583-5329)
- Huicong Liu (ORCID: https://orcid.org/0009-0002-9461-3133)
- Gengpeng Lin
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2025-07-01
- DOI
- https://doi.org/10.2147/ott.s518837
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sun Yat-sen University